Cancers & treatments·Regimen libraryMaintenance

Niraparib maintenance

Checked 2026-09-09

Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status

One cycle

every 28 days × 3 · about 12 weeks in total

28-day cycle × 3 years (PRIMA) or until progression (about 12 weeks)Oral Daily oral course

Components

Drug	Dose	Route	Days	Note
Niraparib Small-molecule PARP inhibitor	200 mg once daily if weight under 77 kg or platelets under 150 × 10⁹/L; otherwise 300 mg	Oral	D1-28

Cycles

3 years (PRIMA) or until progression

28-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Individualised starting dose cut grade 3 thrombocytopenia from 48% to 21%.

Used in

Ovarian cancer

Trials

PRIMA / ENGOT-OV26

Products

Niraparib

Source

PRIMA, NEJM 2019

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.